Across TCGA pan-cancer cohorts, PSMC4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PSMC4 data layer compared with 21 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PSMC4 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated PSMC4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
UCEC, THCA, and ACC are the cancer types where PSMC4 Mutation most reproducibly stratifies survival.